Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17908039 | 0.89 | ALDH1A1 (0.73) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL1282546 | 0.88 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL154613 | 0.85 | NPC1 (0.66) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL2553094 | 0.85 | NPC1 (0.66) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL29399711 | 0.85 | NPC1 (0.66) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL4686068 | 0.85 | IRAK4 (0.56) | ALDH1A1HPGDNPC1TP53RAD52 | |
| SCHEMBL5431477 | 0.85 | ALDH1A1 (0.53) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL28523423 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| SCHEMBL28523421 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KDM4EKMT2AHPGDNPC1 | |
| Hydrochloric Acid SCHEMBL5679748 | 0.84 | NPC1 (0.64) | ALDH1A1KDM4EKMT2AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| CN-103917524-B | Bicyclic heterocycles | ASTELLAS PHARMA INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| CN-103917524-A | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC | 2014-07-09 | — | — | CN | disclosed |
| EP-1272468-B1 | INDOLIN-2-ONE DERIVATIVES, PREPARATION AND THEIR USE AS OCYTOCIN RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2004-03-25 | — | — | US | disclosed |
| US-6673790-B1 | ANTAGONIST OF OXYTOCIN RECEPTORS USED IN COMBINATION WITH ANTAGONIST OF VASOPRESSIN V1A RECEPTORS FOR TREATMENT OF DYSMENORRHEA OR ENDOMETRIOSIS OR CONTROL OF PREMATURE LABOR AND FOR CONTROLLING PREPARATORY LABOR FOR CAESAREAN DELIVERY | SANOFI-SYNTHELABO (FR) | 2004-01-06 | — | — | US | disclosed |
| EP-1272468-A1 | INDOLIN-2-ONE DERIVATIVES, PREPARATION AND THEIR USE AS OCYTOCIN RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001074775-A1 | INDOLIN-2-ONE DERIVATIVES, PREPARATION AND THEIR USE AS OCYTOCIN RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-10-11 | — | — | WO | disclosed |
| US-5686482-A | DOPAMINE RECEPTOR ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0757985-A1 | N-(3-PYRROLIDINYL)BENZAMIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-4342875-A | STABILIZERS FOR OLEFIN POLYMERS | CINCINNATI-MILACRON, INC. (US) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | HSD11B1, HSD17B11, HSD17B1 | ALDH1A1 349/4885KDM4E 3611/4885KMT2A 3204/4885 |
| US-20040059132-A1 | Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them | OXTR, AVPR2, AVPR1B | ALDH1A1 4188/4885KDM4E 3652/4885KMT2A 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.